Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.
Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.
“Many of the new therapies, whether they be targeted agents or immunotherapies are extremely expensive,” he said. “We can get into long debate about what the right or fair price is, but I think because of the high cost, there is a lot of scrutiny in the managed care world to make sure that the right patient gets the treatment.”
He added that it can be difficult to know where treatments belong in the sequence of therapy. While some people are of the opinion that these treatments should be used earlier rather than later, payers prefer to manage to what the FDA decides.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More